SZSE:300573 (China)
Â
Class A
Â¥
70.12
(-0.96%)
Jan 16
Business Description
Shenyang Xingqi Pharmaceutical Co Ltd
ISIN : CNE100002DV1
Share Class Description:
SZSE:300573: Class ACompare
Compare
Traded in other countries / regions
300573.China IPO Date
2016-12-08Description
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company. It produces and sells opthalmic products. Its products include anti-bacterial products, corneal products, anti-inflammation products, anti-allergic, antifungal & among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.04 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 0.61 | |||||
| Interest Coverage | 91.02 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 15.22 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 25 | |||||
| 3-Year EBITDA Growth Rate | 28.4 | |||||
| 3-Year EPS without NRI Growth Rate | 37 | |||||
| 3-Year FCF Growth Rate | 53.6 | |||||
| 3-Year Book Growth Rate | 31.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 61.46 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 56.12 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.56 | |||||
| 9-Day RSI | 45.7 | |||||
| 14-Day RSI | 41.25 | |||||
| 6-1 Month Momentum % | -45.34 | |||||
| 12-1 Month Momentum % | -27.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | |||||
| Quick Ratio | 1.66 | |||||
| Cash Ratio | 1.04 | |||||
| Days Inventory | 129.11 | |||||
| Days Sales Outstanding | 40.43 | |||||
| Days Payable | 14.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.94 | |||||
| Dividend Payout Ratio | 1.46 | |||||
| 3-Year Dividend Growth Rate | 167.4 | |||||
| Forward Dividend Yield % | 1.41 | |||||
| 5-Year Yield-on-Cost % | 51.28 | |||||
| 3-Year Average Share Buyback Ratio | -2.6 | |||||
| Shareholder Yield % | 3.89 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.05 | |||||
| Operating Margin % | 23.68 | |||||
| Net Margin % | 19.34 | |||||
| FCF Margin % | 14.97 | |||||
| ROE % | 21.37 | |||||
| ROA % | 16.86 | |||||
| ROIC % | 26.42 | |||||
| 3-Year ROIIC % | 28.29 | |||||
| ROC (Joel Greenblatt) % | 40.48 | |||||
| ROCE % | 23.76 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 35.08 | |||||
| Forward PE Ratio | 16.2 | |||||
| PE Ratio without NRI | 34.11 | |||||
| Shiller PE Ratio | 84.48 | |||||
| Price-to-Owner-Earnings | 65.83 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 6.8 | |||||
| PB Ratio | 7.55 | |||||
| Price-to-Tangible-Book | 8.61 | |||||
| Price-to-Free-Cash-Flow | 45.18 | |||||
| Price-to-Operating-Cash-Flow | 27.33 | |||||
| EV-to-EBIT | 30.02 | |||||
| EV-to-EBITDA | 30.02 | |||||
| EV-to-Revenue | 6.74 | |||||
| EV-to-FCF | 44.54 | |||||
| Price-to-Projected-FCF | 4.86 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.36 | |||||
| Price-to-Graham-Number | 3.61 | |||||
| Price-to-Net-Current-Asset-Value | 31.59 | |||||
| Earnings Yield (Greenblatt) % | 3.33 | |||||
| FCF Yield % | 2.19 | |||||
| Forward Rate of Return (Yacktman) % | 20.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenyang Xingqi Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,801.998 | ||
| EPS (TTM) (Â¥) | 1.999 | ||
| Beta | 1.55 | ||
| Volatility % | 80.01 | ||
| 14-Day RSI | 41.25 | ||
| 14-Day ATR (Â¥) | 2.781558 | ||
| 20-Day SMA (Â¥) | 71.863 | ||
| 12-1 Month Momentum % | -27.46 | ||
| 52-Week Range (Â¥) | 64.88 - 214.36 | ||
| Shares Outstanding (Mil) | 175.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenyang Xingqi Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenyang Xingqi Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenyang Xingqi Pharmaceutical Co Ltd Frequently Asked Questions
What is Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573)'s stock price today?
The current price of SZSE:300573 is ¥70.12. The 52 week high of SZSE:300573 is ¥214.36 and 52 week low is ¥64.88.
When is next earnings date of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573)?
The next earnings date of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) is .
Does Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) pay dividends? If so, how much?
The Dividend Yield %  of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) is 4.94% (As of Today), Highest Dividend Payout Ratio of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) was 1.94. The lowest was 0.12. And the median was 0.38. The  Forward Dividend Yield % of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) is 1.41%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers